Raquel De Paz Arias

La Paz, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Pathogenic TET2 Variants and Autoinflammatory Manifestations in Myeloid Hematologic Malignancies: Case Report and Literature Review.

Pathogenic TET2 Variants and Autoinflammatory Manifestations in Myeloid Hematologic Malignancies: Case Report and Literature Review.

Journal: European journal of rheumatology

Published: March 03, 2026

One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib.

One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib.

Journal: Annals of hematology

Published: August 14, 2025

Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.

Hepatotoxicity as dose-limiting toxicity of the combination of bosutinib and atezolizumab in patients with chronic myeloid leukemia. Results of the ZEROLMC study.

Journal: Annals of hematology

Published: December 02, 2023

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.

Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.

Journal: Blood advances

Published: February 15, 2022

Lessons learned for successful treatment of AML in the second wave of COVID-19 outbreak.

Lessons learned for successful treatment of AML in the second wave of COVID-19 outbreak.

Journal: Leukemia & lymphoma

Published: March 01, 2021

Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid.

Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid.

Journal: Expert review of hematology

Published: December 07, 2020

No transmission of SARS-CoV-2 in a patient undergoing allogeneic hematopoietic cell transplantation from a matched-related donor with unknown COVID-19.

No transmission of SARS-CoV-2 in a patient undergoing allogeneic hematopoietic cell transplantation from a matched-related donor with unknown COVID-19.

Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis

Published: July 28, 2020

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.

High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.

Journal: Haematologica

Published: August 20, 2018

Nutritional intervention in oncohematological patient.

Nutritional intervention in oncohematological patient.

Journal: Nutricion hospitalaria

Published: January 15, 2012

Showing 1-9 of 9

Last Updated: 09/26/2026